Eesti - eesti - Ravimiamet

novartis baltics sia - oktreotiid - süstesuspensiooni pulber ja lahusti - 30mg 1tk

Eesti - eesti - Ravimiamet

novartis baltics sia - budesoniid - inhalatsioonipulber kõvakapslis - 200mcg 60tk

Eesti - eesti - Ravimiamet

novartis baltics sia - oktreotiid - süstesuspensiooni pulber ja lahusti - 10mg 3tk; 10mg 1tk

Eesti - eesti - Ravimiamet

emdoka - deksametasoon - süstesuspensioon - 1mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

alfasan nederland b.v. - deksametasoon - süstelahus - 2mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

livisto int'l s.l. - deksametasoon - süstelahus - 2mg 1ml 20ml 1tk; 2mg 1ml 50ml 1tk; 2mg 1ml 100ml 6tk; 2mg 1ml 100ml 1tk; 2mg 1ml 20ml 12tk; 2mg 1ml 50ml 12tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

le vet b.v. - prednisoloon - kortikosteroidid süsteemseks kasutamiseks, tavaline, prednisoloon, süsteemsed hormoonpreparaadid, v.a. sugu hormoonide ja insuliini - hobused - hobuste korduva hingamisteede obstruktsiooni (rao) seotud põletikuliste ja kliiniliste parameetrite leevendamine hobustel koos keskkonnakontrolliga.

Eesti - eesti - Ravimiamet

le vet. beheer b.v. - deksametasoon - närimistablett - 0,5mg 80tk; 0,5mg 100tk; 0,5mg 20tk; 0,5mg 40tk; 0,5mg 50tk; 0,5mg 10tk; 0,5mg 70tk; 0,5mg 60tk

Eesti - eesti - Ravimiamet

le vet. beheer b.v. - deksametasoon - närimistablett - 2mg 50tk; 2mg 30tk; 2mg 10tk; 2mg 40tk; 2mg 60tk; 2mg 100tk; 2mg 20tk; 2mg 90tk; 2mg 70tk; 2mg 80tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.